[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"generalized-pustular-psoriasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:generalized-pustular-psoriasis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,72,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100617087","phase-2-a-clinical-trial-of-tqh2929-injection-in-patients-with-acute-flare-up-of-generalized-pustular-psoriasis-100617087",false,"NCT07314060","A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH2929 Injection in Patients With Acute Exacerbations of Generalized Pustular Psoriasis","Inclusion Criteria:\n\n* Age ≥ 18 or ≤75 years old at screening, regardless of gender;\n* Meet the diagnostic criteria defined by the 2017 European Society for Clinical Nutrition and Metabolism (ESPEN) Research Workshop (ERASPEN) consensus and be diagnosed as （generalized pustular psoriasis(GPP);\n* Compliant with GPP acute onset;\n* Able to read and understand, and willing to sign the informed consent form;\n* Willing and compliant with study visits and related procedures;\n* Female subjects of childbearing age should agree that contraceptive measures must be used during the study and for 6 months after the end of the study;\n\nExclusion Criteria:\n\n* Pustules are limited to psoriasis vulgaris on psoriasis plaques;\n* Concomitant skin disease or medical disease that may interfere with the investigator's evaluation of the subject's treatment response;\n* Presence of severe, progressive, or uncontrolled disease, or signs and symptoms that are not suitable for participation in the investigator, in the judgment of the investigator:\n* Serum virological abnormalities during the screening period;\n* Chest radiology examination shows that the subject has active tuberculosis or a history of contact with open tuberculosis subjects in the past 6 months or a positive Interferon-Gamma Release Assays(IGRA) test;\n* History of serious infection leading to hospitalization within 2 months prior to baseline;\n* Active infection requiring systemic antibiotics, systemic antifungals, or systemic antiviral therapy within 2 weeks prior to baseline, according to the investigator's assessment;\n* History of opportunistic infection within 6 months prior to baseline;\n* Received live (attenuated) vaccine treatment within 12 weeks prior to baseline;\n* Any major surgery within 4 weeks prior to baseline or planned major surgery during the study;\n* Received blood transfusion within 4 weeks prior to baseline;\n* Participated in clinical trials of other drugs or medical devices within 4 weeks before baseline;\n* Any known or suspected congenital or acquired immunodeficiency state or condition that may compromise the subject's immune status;\n* Subjects with any type of active malignancy or a history of malignancy;\n* Alcohol, drug and known drug dependence;\n* Pregnant or lactating women;\n* Subjects cannot tolerate intravenous infusion administration.","ALL","18 Years","75 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection\u002Fplacebo. The aim was to demonstrate the efficacy and safety of TQH2929 injection in patients with acute exacerbations of generalized pustular psoriasis, with a total of 36 subjects.",[27],"Generalized Pustular Psoriasis","RECRUITING","2026-03-20",{"date":31,"type":32},"2026-03-24","ACTUAL",{"date":34,"type":32},"2026-03-19",{"date":36,"type":21},"2027-07",{"name":38,"class":39},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","INDUSTRY",32,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100627422","generalized-pustular-psoriasis-registry-in-costa-rica-100627422","NCT07448428","Generalized Pustular Psoriasis Registry in Costa Rica","National Registry of Patients With Generalized Pustular Psoriasis Treated Within the Costa Rican Social Security System","Inclusion Criteria:\n\n* Confirmed diagnosis of generalized pustular psoriasis (GPP) established by a board-certified dermatologist based on compatible clinical and\u002For histopathologic criteria.\n* Registered diagnosis of GPP in the institutional electronic health record system (EDUS code L401) during the study period.\n* Patients of any age and sex receiving care within participating centers of the Costa Rican Social Security system.\n* Availability of clinical information sufficient for registry data entry and follow-up according to routine care.\n\nExclusion Criteria:\n\n* Patients without a confirmed diagnosis of generalized pustular psoriasis (GPP) or with alternative pustular dermatoses (e.g., acute generalized exanthematous pustulosis) not meeting GPP diagnostic criteria.\n* Absence of verifiable diagnosis in the institutional electronic health record (EDUS) or insufficient documentation to confirm GPP.\n* Patients whose clinical records lack the minimum data required for registry variables or follow-up within routine care.",{"count":49,"type":21},50,"5 Years","OBSERVATIONAL","The goal of this observational registry study is to characterize the clinical, epidemiological, and therapeutic features of patients with generalized pustular psoriasis (GPP) in Costa Rica through a standardized national registry. The main question it aims to answer is:\n\nWhat are the clinical, epidemiological, and therapeutic characteristics of patients with generalized pustular psoriasis registered in the country, and how do these relate to disease severity and evolution?\n\nPatients with GPP receiving routine dermatologic care in participating centers will have their demographic, clinical, severity, comorbidity, and treatment data recorded using a standardized case report form. Clinical assessments (e.g., GPPASI, PASI\u002FBSA, DLQI), laboratory results, triggers, complications, and therapies will be documented and updated during periodic follow-up visits as part of usual care.",[27,54],"Generalized Pustular Psoriasis (GPP)",[56,57,58,59],"Psoriasis","Registry","Costa Rica","Generalized pustular psoriasis","NOT_YET_RECRUITING","2026-03-06",{"date":63,"type":32},"2026-03-09",{"date":65,"type":21},"2026-05",{"date":67,"type":21},"2031-05",{"name":69,"class":70},"Caja Costarricense de Seguro Social","OTHER_GOV",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":71},"100523844","corevitas-generalized-pustular-psoriasis-gpp-drug-safety-and-effectiveness-registry-100523844","NCT06100991","CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry","Inclusion Criteria:\n\n* A subject must meet all the following criteria to participate in the registry:\n\n  1. Has been diagnosed with GPP by a dermatologist or a qualified dermatology practitioner.\n  2. Is at least 18 years of age and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted.\n  3. Is willing to provide consent for participation in the registry.\n  4. Is willing to provide Personal Information\n\nExclusion Criteria:\n\n* Any of the following would exclude the subject from participating in the registry:\n\n  1. Is participating or planning to participate in a blinded clinical trial evaluating a systemic agent for the treatment or prevention of flares related to GPP.\n  2. Is enrolled in another CorEvitas registry for a dermatological condition. Subjects enrolled in another CorEvitas registry must be exited to be eligible for enrollment into the GPP Registry",true,{"count":80,"type":21},200,"Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target",[27],"2026-02-04",{"date":85,"type":32},"2026-02-09",{"date":87,"type":32},"2023-09-19",{"date":89,"type":21},"2099-12",{"name":91,"class":92},"CorEvitas","NETWORK",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100552780","phase-2-long-term-safety-and-efficacy-of-hb0034-in-subjects-with-generalized-pustular-psoriasis-100552780","NCT06477536","Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis","A Phase IIb, Long-Term Extension Study to Evaluate the Safety and Efficacy of HB0034 in the Treatment of Adult Subjects With Generalized Pustular Psoriasis","Inclusion Criteria:\n\n* Patients participated in the preceding placebo-controlled Phase 2 study （HB0034-04）and completed at least the Week 12 visit of the HB0034-04 study\n* Subject must be a candidate for prolonged GPP treatment according to the Investigator's judgment\n* Men and women of reproductive age who have no parenting plans and are willing to use reliable contraception during the study period and for 6 months after the last dose of the study drug;\n* Patients who fully understand and voluntarily sign an ICF, and are willing and able to follow clinical study and subsequent visit schedules\n\nExclusion Criteria:\n\n* Patients who are experiencing GPP flare",{"count":101,"type":21},33,[24,103],"PHASE3","This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).",[27],"2025-02-12",{"date":108,"type":32},"2025-02-14",{"date":110,"type":32},"2024-09-02",{"date":112,"type":21},"2026-06-30",{"name":114,"class":39},"Shanghai Huaota Biopharmaceutical Co., Ltd.",3]